Literature DB >> 8498814

Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan.

L M DeAngelis1.   

Abstract

Cerebral lymphoma is usually identified on computed tomographic/magnetic resonance scan as a homogeneously contrast-enhancing periventricular mass lesion. We present 10 patients with cerebral lymphoma who had nonenhancing tumor on computed tomographic (2 patients) or magnetic resonance scan (8 patients) either at the time of diagnosis or recurrence. The absence of enhancement caused diagnostic delay in all patients and suggests that tumor resides behind an intact blood-brain barrier, raising important therapeutic implications in the design of chemotherapeutic regimens.

Entities:  

Mesh:

Year:  1993        PMID: 8498814     DOI: 10.1002/ana.410330313

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

Review 1.  Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications.

Authors:  S I Rapoport
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

2.  Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study.

Authors:  Y Shibamoto; K Sasai; N Oya; M Hiraoka
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

Review 3.  Multifocal presentation of medulloblastoma in adulthood.

Authors:  Pietro Ciccarino; Antonino Rotilio; Marta Rossetto; Renzo Manara; Enrico Orvieto; Franco Berti; Giuseppe Lombardi; Domenico d'Avella; Renato Scienza; Alessandro Della Puppa
Journal:  J Neurooncol       Date:  2011-11-10       Impact factor: 4.130

4.  Non-enhancing primary CNS lymphoma.

Authors:  M L Lachenmayer; E Blasius; P Niehusmann; A Kovacs; M Stuplich; O Eichler; M Glas; H Urbach; Ulrich Herrlinger
Journal:  J Neurooncol       Date:  2010-06-09       Impact factor: 4.130

5.  Nonenhancing primary central nervous system lymphoma.

Authors:  S Terae; A Ogata
Journal:  Neuroradiology       Date:  1996-01       Impact factor: 2.804

6.  MRI findings of primary CNS lymphoma in 26 immunocompetent patients.

Authors:  Dong Zhang; Liang-Bo Hu; Tobias D Henning; Elisabeth M Ravarani; Li-Guang Zou; Xiao-Yuan Feng; Wen-Xian Wang; Li Wen
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

7.  Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.

Authors:  B P O'Neill; T M Habermann; T E Witzig; M Rodriguez
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 8.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

9.  Post-treatment T1 shortening in primary CNS lymphoma.

Authors:  Sasan Karimi; Vaios Hatzoglou; Vineet Punia; Sasan Partovi; Lauren E Abrey; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2012-10-17       Impact factor: 4.130

Review 10.  A case of 'lymphomatosis cerebri' diagnosed in an early phase and treated by whole brain radiation: case report and literature review.

Authors:  Ryuichi Kanai; Makoto Shibuya; Takashi Hata; Makoto Hori; Kenichi Hirabayashi; Tadashi Terada; Koji Fujii
Journal:  J Neurooncol       Date:  2007-07-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.